Predictive Immunohistochemistry in Cholangiocarcinoma: Current Clinical Utility, Practical Limitations, and Emerging...

Area of Science:

• Oncology
• Pathology
• Biomarker Discovery

Background:

• Cholangiocarcinoma (CCA) is a challenging biliary tract cancer requiring precise therapeutic strategies.
• Biomarker-driven patient stratification is crucial for optimizing CCA treatment outcomes.
• Immunohistochemistry (IHC) offers a practical, rapid, and tissue-sparing alternative to molecular testing for biomarker detection.

Purpose of the Study:

• To review the current and emerging clinical utility of predictive IHC biomarkers in CCA.
• To discuss interpretative challenges and integration strategies with molecular testing.
• To highlight future directions in IHC-based biomarker research for CCA.

Main Methods:

• Narrative review of existing literature on predictive IHC in CCA.
• Analysis of the clinical relevance and limitations of established and investigational IHC markers.
• Discussion of advanced techniques like digital image analysis and machine learning for biomarker quantification.

Main Results:

• HER2 and mismatch repair proteins are currently the most clinically relevant IHC markers in select CCA patient subsets.
• PD-L1 has biological significance but limited standalone utility for treatment selection in CCA.
• Claudin 18.2 is a promising investigational marker, with ongoing research into other biomarkers and advanced analytical methods.

Conclusions:

• IHC plays a vital role in CCA biomarker-based treatment stratification, complementing molecular testing.
• Careful interpretation and integration with molecular data are essential for maximizing IHC's clinical impact.
• Future research focusing on novel biomarkers and digital pathology holds promise for refining patient selection in CCA.